drugset / Trial / NCT03020134

Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China

NCT03020134

Phase 1 Completed 18 enrolled Ascletis Pharmaceuticals Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the Pharmacokinetics and safety of Ravidasvir in Combination with Ritonavir-boosted Danoprevir in Single and Multiple doses in Healthy Participants

Timeline

Start
2016-07-15
Primary completion
2016-08-22
Completion
2016-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Ravidasvir Small molecule 200 mg Oral
Subject Ritonavir Other / unclassified 100 mg Oral
Subject danoprevir Small molecule 100 mg Oral

Indications

No indication recorded.